Associated Papers
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.
Aptullahoglu E et al.
Cancers, 2025
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.
Aptullahoglu E et al.
International Journal of Molecular Sciences, 2023
36768733 (PubMed )
Supplement: ijms-24-02410-s001.zip › ijms-2135245-supplementary.pdf
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM et al.
Pharmacological Reviews, 2022
Germline TP53 mutational spectrum in French Canadians with breast cancer.
Arcand SL et al.
Bmc Medical Genetics, 2015
TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset.
Pinto C et al.
Familial Cancer, 2009
Select a paper to view details